Last reviewed · How we verify
Pediacel®
Pediacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.
Pediacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | Pediacel® |
|---|---|
| Also known as | DTaP-IPV-Hib, Sanofi-Pasteur-MSD's combined DTPa-inactivated polio-Haemophilus influenzae type b vaccine. |
| Sponsor | MCM Vaccines B.V. |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | FDA-approved |
Mechanism of action
Pediacel contains inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, and conjugated Haemophilus influenzae type b polysaccharide. These components trigger adaptive immune responses, generating humoral and cellular immunity to protect against these five infectious diseases. The vaccine is administered intramuscularly in a series of doses during infancy and childhood.
Approved indications
- Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants (NA)
- Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (PHASE3)
- Vaccinating Children After Chemotherapy (PHASE4)
- Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
- Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pediacel® CI brief — competitive landscape report
- Pediacel® updates RSS · CI watch RSS
- MCM Vaccines B.V. portfolio CI